BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10155583)

  • 1. New developments in pricing and drug reimbursement in France.
    Pelc A; Castan JP
    Pharmacoeconomics; 1994; 6 Suppl 1():28-35. PubMed ID: 10155583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
    Rigter H
    Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The French medecine pricing committee and the medicine economic policy: Rules and competences].
    Giorgi D
    Ann Pharm Fr; 2017 Sep; 75(5):359-372. PubMed ID: 28522031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European pharmaceutical pricing and reimbursement conference.
    Ehreth J; Williams D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
    Gross DJ; Ratner J; Perez J; Glavin SL
    Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing and reimbursement of pharmaceuticals: an evaluation of cost-containment strategies. Proceedings of a symposium. Talloires, France, July 21-22, 1993.
    Pharmacoeconomics; 1994; 6 Suppl 1():1-87. PubMed ID: 10184441
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug pricing and reimbursement in France. Towards a new model?
    Le Pen C
    Pharmacoeconomics; 1996; 10 Suppl 2():26-36. PubMed ID: 10163433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
    Hsu JC; Lu CY
    Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pricing and reimbursement of pharmaceuticals.
    Towse A
    Pharmacoeconomics; 1994; 6 Suppl 1():36-8. PubMed ID: 10155584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology.
    Nguyen HP; Go JA; Barbieri JS; Stough D; Stoff BK; Forman HP; Bolognia JL; Albrecht J;
    J Am Acad Dermatol; 2020 Aug; 83(2):691-699. PubMed ID: 32330637
    [No Abstract]   [Full Text] [Related]  

  • 14. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving health-care regulations in China.
    Ouyang Y
    Lancet Oncol; 2017 Jun; 18(6):714. PubMed ID: 28528748
    [No Abstract]   [Full Text] [Related]  

  • 18. [Price of medications: the actual system must be seen again].
    Mayencourt J
    Rev Med Suisse; 2016 Mar; 12(508):479. PubMed ID: 27089613
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public policy trends in drug pricing and reimbursement in the European Community.
    Redwood H
    Pharmacoeconomics; 1994; 6 Suppl 1():3-10. PubMed ID: 10172481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.